Summary
We gave 12 healthy male volunteers 1 mg of alprazolam or placebo on three occasions after a standard breakfast in a double-blind, randomized, single-dose, three-way crossover study.
The three trials were: (a) oral alprazolam and sublingual placebo; (b) oral placebo and sublingual alprazolam; (c) placebo by both routes.
Plasma alprazolam concentrations during 24 h after each dose were measured by electron-capture gas-liquid chromatography.
Peak plasma concentrations were reached later after sublingual than oral dosage (2.8 vs 1.8 h, P<0.01). Other kinetic variables were not significantly different: peak plasma concentration, 11.3 vs 12.0 ng·ml−1; elimination half-life, 12.5 vs 11.7 h; and total area under the plasma concentration versus time curve, 197 vs 186 h·ng·ml−1.
Pharmacodynamic measures showed that sublingual and oral alprazolam both produced sedation, fatigue, impaired digit symbol substitution, slowing of reaction time, and impairment of the acquisition and recall of information. These changes were initially observed at 0.5 h after dosage and lasted up to 8 h.
In general the two routes were significantly different from placebo but not from each other.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Dawson GW, Jue SG, Brogden RN (1984) Alprazolam: a review of its pharmacodynamic properties and efficacy in the treatment of anxiety and depression. Drugs 27: 132–147
Fawcett JA, Kravitz HM (1982) Alprazolam: pharmacokinetics, clinical efficacy, and mechanism of action. Pharmacotherapy 2: 243–254
Greenblatt DJ, Divoll M, Abernethy DR, Moschitto LJ, Smith RB, Shader RI (1983) Alprazolam kinetics in the elderly. Arch Gen Psychiatry 40: 287–290
Scavone JM, Greenblatt DJ, Shader RI (1987) Alprazolam kinetics following sublingual and oral administration. J Clin Psychopharmacol 7: 332–334
Greenblatt DJ, Divoll M, Abernethy DR, Ochs HR, Shader RI (1983) Clinical pharmacokinetics of the newer benzodiazepines. Clin Pharmacokinet 8: 233–252
Smith RB, Kroboth PD, Vanderlugt JT, Phillips JP, Juhl RP (1984) Pharmacokinetics and pharmacodynamics of alprazolam after oral and IV administration. Psychopharmacology 84: 452:456
Fujii J, Inotsume N, Nakamo M (1990) Effect of food on the bioavailability of bromazepam following oral administration in healthy volunteers J. Pharmacobio-Dyn 13: 269–271
Greenblatt DJ, Allen MD, MacLaughlin DS, Harmatz JS, Shader RI (1978) Diazepam absorption: effects of antacids and food. Clin Pharmacol Ther 24: 600–609
Divoll M, Greenblatt DJ, Ciraulo DA (1982) Clobazam kinetics: intrasubject variability, and effect of food on absorption. J Clin Pharmacol 22: 69–73
Bornemann LD, Crews T, Chen SS, Twardak S, Patel IH (1986) Influence of food on midazolam absorption. J Clin Pharmacol 26: 55–59
Greenblatt DJ, Shader RI (1987) Drug absorption rate: A critical component of bioequivalence assessment in psychopharmacology. J Clin Pharmacol 27: 85–86
Scavone JM, Greenblatt DJ, Friedman H, Shader RI (1986) Enhanced bioavailability of triazolam following sublingual versus oral administration. J Clin Pharmacol 26: 208–210
Clausen TG, Boysen K, Wolff J, Larsen F (1989) Plasma concentrations of bromazepam following peroral and sublingual administration. Pharmacol Toxicol 64: 389–390
Greenblatt DJ, Divoll M, Harmatz JS, Shader RI (1982) Pharmacokinetic comparison of sublingual lorazepam with intravenous, intramuscular and oral lorazepam. J Pharm Sci 71: 248–252
Taüber U, Tack JW, Dorow R (1984) Plasma levels of lormetazepam after sublingual and oral administration of 1 mg to humans. Drug Dev Ind Pharmacy 10: 1587–1596
Hüttel MS, Bang U (1985) Sublingual flunitrazepam for premedication. Acta Anaesth Scand 29: 209–211
Greenblatt DJ, Harmatz JS, Dorsey C, Shader RI (1988) Comparative single-dose kinetics and dynamics of lorazepam, alprazolam, prazepam, and placebo. Clin Pharmacol Ther 44: 326–334
Greenblatt DJ, Abernethy DR, Morse DS, Harmatz JS, Shader RI (1984) Clinical importance of the interaction of diazepam and cimetidine. N Engl J Med 310: 1639–1643
Shader RI, Dreyfuss D, Gerrein JR, Harmatz JS, Allison SJ, Greenblatt DJ (1986) Sedative effects and impaired learning and recall after single oral doses of lorazepam. Clin Pharmacol Ther 39: 526–529
Greenblatt DJ, Harmatz JS, Engelhardt N, Shader RI (1989) Pharmacokinetic determinants of dynamic differences among three benzodiazepine hypnotics: flurazepam, temazepam, and triazolam. Arch Gen Psychiatry 46: 326–332
Wittenborn JR (1979) Effects of benzodiazepines on psychomotor performance. Br J Clin Pharmacol 7: 61S-67S
Wechsler D (1955) Manual for the Wechsler Adult Intelligence Scale. New York, Psychological Corporation
Greenblatt DJ, Harmatz JS, Shapiro L, Engelhardt N, Gouthro TA, Shader RI (1991) Sensitivity to triazolam in the elderly. N Engl J Med 46: 326–322
Greenblatt DJ, Divoll M, Moschitto LJ, Shader RI (1981) Electron-capture gas chromatographic analysis of the triazolobenzodiazepines alprazolam and triazolam. J Chromatogr 225: 202–207
Greenblatt DJ, Javaid JI, Locniskar A, Harmatz JS, Shader RI (1990) Gas chromatographic analysis of alprazolam in plasma: replicability, stability, and specificity. J Chromatogr 534: 202–207
Ghoneim MM, Mewaldt SP (1990) Benzodiazepines and human memory: A review. Anesthesiology 72: 926–938
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Scavone, J.M., Greenblatt, D.J., Goddard, J.E. et al. The pharmacokinetics and pharmacodynamics of sublingual and oral alprazolam in the post-prandial state. Eur J Clin Pharmacol 42, 439–443 (1992). https://doi.org/10.1007/BF00280132
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF00280132